
    
      The study had a maximum study duration of 29 weeks, which consisted of a 3-week screening
      period (including a possible 1-week delay in first investigational medicinal product [IMP]
      administration after randomization in virtual group due to shipment of IMP and the virtual
      devices), a 24-week treatment period, and 1-week post-treatment safety follow-up period.
    
  